UNITED STATES
SECURITIES AND EXCHANGE
COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the
Securities Exchange Act of
1934
Date of Report (Date of earliest event
reported): October
22,
2010
MICROMET,
INC.
(Exact Name of Registrant as Specified in
its Charter)
|
Delaware
|
0-50440
|
52-2243564
|
|
(State or Other
Jurisdiction
|
(Commission
|
(IRS
Employer
|
|
of
Incorporation)
|
File
Number)
|
Identification
No.)
|
|
|
|
|
6707
Democracy Boulevard, Suite 505, Bethesda, MD
|
20817
|
|
(Address of Principal Executive
Offices)
|
(Zip
Code)
|
Registrant’s telephone number, including area code:
(240)
752-1420
|
|
|
(Former Name or Former Address, if
Changed Since Last
Report.)
|
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions (see General Instruction A.2.
below):
|
o
|
Written
communications
pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
|
|
o
|
Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
|
o
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
|
|
o
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
|
Section 7
– Regulation FD
Item 7.01.
Regulation FD Disclosure
The
information contained in this Item 7.01 shall not be deemed filed for
purposes of Section 18 of the Securities Exchange Act of 1934, as amended
(the “Exchange Act”), or incorporated by reference in any filing under the
Exchange Act or the Securities Act of 1933, as amended, except as shall be
expressly set forth by specific reference in such filing.
Micromet,
Inc. (the “Company”) is furnishing this information to disclose that it has
recalled a batch of diluent, a liquid used to dilute MT110 drug product for
administration to patients. The recall was necessary because of potential
damage to the primary packaging material of the diluent. Due to the batch
recall, the Company currently does not have diluent available for the ongoing
phase 1 clinical trial with MT110 and is therefore not treating patients in the
trial. Production of a new batch of diluent is ongoing at a third party
manufacturer and the Company expects to resume treatment of patients in the
phase 1 trial in the first quarter of 2011. The Company expects to provide an
update on data from the clinical trial in the second half of 2011.
SIGNATURES
Pursuant to the requirements of the
Securities Exchange Act of 1934, the registrant has duly caused this report to
be signed on its behalf by the undersigned hereunto duly
authorized.
|
MICROMET,
INC.
|
|||
|
Date: October 22,
2010
|
By:
|
/s/ Matthias
Alder
|
|
|
Name:
|
Matthias
Alder
|
||
|
Title:
|
Senior Vice President &
General
Counsel
|
||